These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25741561)

  • 41. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent primary angiosarcoma and invasive ductal carcinoma in the same breast.
    Ni Y; Xie X; Bu H; Zhang Z; Wei B; Yin L; Chen M; Chen H; Zhang H
    J Clin Pathol; 2013 Mar; 66(3):263-4. PubMed ID: 23172554
    [No Abstract]   [Full Text] [Related]  

  • 43. Objective response rate as a surrogate end point: a commentary.
    Fleming TR
    J Clin Oncol; 2005 Aug; 23(22):4845-6. PubMed ID: 15955898
    [No Abstract]   [Full Text] [Related]  

  • 44. Intermediate endpoints of primary systemic therapy in breast cancer patients.
    Berruti A; Generali D; Bertaglia V; Brizzi MP; Mele T; Dogliotti L; Bruzzi P; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):142-6. PubMed ID: 22043062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anthracycline war: no victor yet.
    Young P
    J Natl Cancer Inst; 2009 Sep; 101(17):1171-3. PubMed ID: 19706625
    [No Abstract]   [Full Text] [Related]  

  • 46. An unusual triple-negative breast carcinoma.
    Shousha S; Peston D; Gojis O; Palmieri C
    Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
    [No Abstract]   [Full Text] [Related]  

  • 47. Does breast cancer tumor size really matter that much?
    Provencher L; Diorio C; Hogue JC; Doyle C; Jacob S
    Breast; 2012 Oct; 21(5):682-5. PubMed ID: 22835917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
    Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 50. Improved prognosis for biomarkers in breast cancer.
    Dowsett M
    Lancet; 1998 Jun; 351(9118):1753-4. PubMed ID: 9635946
    [No Abstract]   [Full Text] [Related]  

  • 51. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast cancer.
    Ring A; Harper-Wynne C; Smith I
    Cancer Chemother Biol Response Modif; 2005; 22():545-61. PubMed ID: 16110628
    [No Abstract]   [Full Text] [Related]  

  • 53. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 54. Biological variables and prognosis of DCIS.
    van de Vijver MJ
    Breast; 2005 Dec; 14(6):509-19. PubMed ID: 16246564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Gene expression analysis and its clinical use in breast tumors].
    Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
    Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunology: Another shot at cancer.
    Schmidt C
    Nature; 2015 Nov; 527(7578):S105-7. PubMed ID: 26580157
    [No Abstract]   [Full Text] [Related]  

  • 58. Randomised trials: the case for science in medicine.
    Baum M
    Recent Results Cancer Res; 1988; 111():6-17. PubMed ID: 3051231
    [No Abstract]   [Full Text] [Related]  

  • 59. Progress in inflammatory breast cancer: cause for cautious optimism.
    Hortobagyi GN; Buzdar AU
    J Clin Oncol; 1986 Dec; 4(12):1727-9. PubMed ID: 3783199
    [No Abstract]   [Full Text] [Related]  

  • 60. Using a database of protocol studies to evaluate therapy: a breast cancer example.
    Moon TE; Jones SE; Bonadonna G; Powles TJ; Rivkin S; Buzdar A; Montague E
    Stat Med; 1984; 3(4):333-9. PubMed ID: 6528133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.